Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
CA 2436699 A1 · Owner: Scott, Ian Leslie · Inventors: Scott, Ian Leslie; Nikam, Sham Shridhar; Lewthwaite, Russell Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described are piperlines of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) ar antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as for , example, stroke, cerebral ischemia central nervous system disorders, depression trauma, hypoglycemia, neurodegenerative disorders anxiety, migraine headache, convulsions Parkinson's disease, aminoglycoside , antibiotics-induced hearing loss psychosis, glaucoma, CMV retitins, opioid tolerance or withdrawal, pain, especially chronic pain neuropathic pain, or , surgical pain, or urinary incontinence.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 30, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 30, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 30, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.